Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 222

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 222
---
 Executive Officers of the companies belonging to the pharmaceutical panel was approximately €1,768,000; the median of the annual variable compensation awarded was in the region of €3,074,000; and the median of the long-term compensation awarded (whether equity-based or in cash) represented approximately 922% of fixed compensat ion. In 2024, Paul Hudson’s overall compensation (fixed, variable and equity-based) was within in the first quartile of the panel, whereas in 2023 it was in the lower range of the second quartile . Review of the Chief Executive Officer's compensation at the Board meeting of February 12, 2025 The quantum and structure of the Chief Executive Officer's compensation, which had been unchanged since 2022, were subject to an in-depth review by the Board of Directors at their meeting of February 12, 2025. Issues considered by the Board included: • Sanofi's performance during the 2022-2024 period, including (i) the continuation of the Play to Win strategy led by Paul Hudson, involving a major transformation in our profile to a global immunology leader combined with the separation of our Consumer Healthcare business; (ii) further successful launches; and (iii) favorable readouts from a number of Phase 3 studies; • Paul Hudson's international profile, reflecting his thorough understanding and recognized international experience of the pharmaceutical industry and his ability, since his appointment, to develop an ambitious strategy in a competitive, concentrated sector, combined with the need to ensure continuity (with support from the Executive Committee) in delivering this strategy in the years ahead – including performance improvement and change management, especially in our R&D teams; and • trends in compensation practices for the Chief Executive Officers of the panel companies mentioned above, the relative ranking of Sanofi, and the widening gap with the panel of pharmaceutical companies, given that Paul Hudson's compensation has been reviewed only once since he took office in 2019, with a 7.7% increase in his annual fixed compensation and 10% in his equity- based compensation in 2022.

| 128 | SANOFIFORM 20-F2024 |

| PART I                                             |
| ITEM 6. Directors, Senior Management and Employees |

Following this latest review, our Board of Directors, acting on a recommendati on from the Compensation Committee, decided to (i) raise the Chief Executive Officer's annual fixed compensation to €1,600,000, a 14.3% rise (equivalent to 4.77